Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade

doi:10.4254/wjh.v9.i2.74

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7371)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

512

WORD

339

HTML

3640

Figures (1-1)

596

Sum=5087

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

939

Download

1345

Sum=2284

Jan 18, 2017 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Jan 18, 2017; 9(2): 74-79
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.74

Open in New Tab Full Size Figure Download Figure

Figure 1 Overview of angiotensin receptor blockers actions on the liver. ARBs reduce hepatic steatosis through favored beta-oxidation and reduced insulin resistance. Concomitantly, it indirectly enhances Mas receptor activity, eliciting hepatoprotective effects by low TGF-beta1 expression, which limits hepatic stellate cells activation and prevents liver fibrosis. ARBs: Angiotensin receptor blockers; TGF-beta1: Transforming growth factor-beta 1.

Citation: Souza-Mello V. Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade. World J Hepatol 2017; 9(2): 74-79
URL: https://www.wjgnet.com/1948-5182/full/v9/i2/74.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i2.74